• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187154 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  % ^9 L, \! k/ o8 ]- I
8 l9 W, U2 b+ r5 d2 @
* ?5 i% X% {% G0 \: L
Sub-category:
" B/ Q0 v- K: G8 R9 C# {Molecular Targets
# K0 g/ c+ \6 i; g! o  i" y# I, }6 w- f

' r2 \$ W% C( o  \# KCategory:+ u  ~$ \/ ^- W) ^% R1 X
Tumor Biology   |9 t2 L# U" [/ u; I, H

0 i6 A5 \2 _* r( R" F" V
4 y7 h$ D9 l- W/ r/ `) C/ v( k: iMeeting:6 F, m* e- Z5 H& s
2011 ASCO Annual Meeting   m5 S+ z+ Y. g, q

/ l# \, `! [- e' M2 q2 Q) @0 j6 U! k
+ A; m' b3 _9 v9 z* cSession Type and Session Title:  r: _" b( L, f0 h5 _4 o
Poster Discussion Session, Tumor Biology
( W9 D0 e: X( S, a5 w/ R
, M, t! p8 c" W  W# z/ i
1 ~3 a# U% S3 [) z- w4 M( D7 Y# H* RAbstract No:$ x* A( M& }) M9 x
10517 0 s2 M0 ^* J. x4 \* @+ B

; t- c( T# {  i, @  K. u9 x5 Q- Y
1 ~( Y6 J* ^9 XCitation:
) a  F$ `( a+ K9 M6 m" A6 k: QJ Clin Oncol 29: 2011 (suppl; abstr 10517)
0 E; C4 W- h  {1 L% C0 u5 Q/ W- L) g+ }! t9 \, g5 w7 S' K: X

2 H# @' f/ n3 `$ g8 Z7 X7 x% NAuthor(s):
# z- K9 A9 B, h( Z+ p/ c: yJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) l# t; a: p( Q/ C5 ^2 s# u
- A$ A. g( ~8 l* N8 i  R6 c8 \, _

" G* k+ L! z! ~" t. b; x7 `0 K+ U2 o9 h% L
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.1 f! |# W8 u$ ?- h% S9 w

0 N/ z  Z: N, I+ eAbstract Disclosures
4 \0 M0 K  t3 Q" ]: z6 N
/ T' Y& \0 h7 `  MAbstract:
- `$ X/ l" c. O& r5 l9 F( {( {+ c
! E9 d$ T5 `) C* |' X  \' c; ?8 k
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
; X4 }; i& [, n! D' t- Q. Z% A, L6 A- n
) v0 k  y1 Z; n0 k+ T+ m; [8 S
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
- ^4 M' b+ ^8 Z6 i2 S没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

/ \0 V' ~  e- J; {$ }: R' ]) l化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 4 y+ ]. _6 @: x/ M/ Q0 I/ v
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。$ ]+ a4 @4 W7 A5 {* A
ALK一个指标医院要900多 ...

3 Q% D- v% g7 ^8 X平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?4 d+ i4 S1 r! s6 s- O
2 A8 H' g5 u9 i: t
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表